| Evolus, Inc. (EOLS) Reports Q1 Loss, Misses Revenue Estimates |
Evolus, Inc. (EOLS) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.10. This compares to loss of $0.13 per share a year ago. |
zacks.com |
2025-05-07 23:55:33 |
Czytaj oryginał (ang.) |
| Evolus, Inc. (EOLS) Q1 2025 Earnings Call Transcript |
Evolus, Inc. (NASDAQ:EOLS ) Q1 2025 Earnings Conference Call May 7, 2025 4:30 PM ET Company Participants Nareg Sagherian - VP, Head of Global IR and Corporate Communications David Moatazedi - President and CEO Sandra Beaver - CFO Conference Call Participants Annabel Samimy - Stifel Marc Goodman - Leerink Partners Navann Ty - BNP Paribas Serge Belanger - Needham Doug Tsao - H.C. Wainwright Sam Eiber - BTIG Operator Good afternoon, everyone. |
seekingalpha.com |
2025-05-07 23:13:09 |
Czytaj oryginał (ang.) |
| Evolus Strengthens Balance Sheet with Refinancing; Reducing Cost of Capital and Expanding Financial Flexibility |
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced it has entered into an amended and restated credit facility, replacing its existing $125 million credit agreement with a new $250 million credit facility with funds managed by Pharmakon Advisors, LP. Highlights of the new facility include: Lowered Interest Rate: Reduced borrowing cost by 350 basis points (bps) based. |
businesswire.com |
2025-05-05 20:05:00 |
Czytaj oryginał (ang.) |
| Will Evolus, Inc. (EOLS) Report Negative Earnings Next Week? What You Should Know |
Evolus (EOLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-04-30 15:06:47 |
Czytaj oryginał (ang.) |
| Evolus to Report First Quarter Financial Results on May 7, 2025 |
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its first quarter 2025 financial results on Wednesday, May 7, 2025, after the U.S. financial markets close. Evolus management will host a conference call and live webcast to discuss these results at 4:30 p.m. ET that same day. A question-and-answer session will follow management's remarks. To par. |
businesswire.com |
2025-04-23 12:00:00 |
Czytaj oryginał (ang.) |
| Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant in April of an aggregate of 30,579 restricted stock units (RSUs) of the company's common stock to 13 newly hired non-executive employees of the company. The awards were approved by the compensation committee of the company's board of directors under the Evolus' 2023 Inducement Incentive Plan, with a grant d. |
businesswire.com |
2025-04-18 20:05:00 |
Czytaj oryginał (ang.) |
| Evolus Announces Commercial Launch of Evolysse™ |
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced the commercial launch date for Evolysse™ Form and Evolysse™ Smooth injectable hyaluronic acid (HA) gels, the first two products in the Evolysse™ collection, scheduled for Friday, April 18th. To support the introduction, Evolus will initiate a comprehensive educational rollout beginning with a national Evolus Academy webcast for health. |
businesswire.com |
2025-04-16 12:00:00 |
Czytaj oryginał (ang.) |
| Evolus Launches “Drop the F Word” Campaign in Advance of the Commercial Launch of Evolysse™ Injectable Hyaluronic Acid Gels |
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced the launch of its bold new campaign, “Drop the F Word,” ahead of the upcoming commercial launch of Evolysse™. Designed to challenge outdated perceptions and language in the aesthetics industry, the campaign introduces Evolysse™, a collection of injectable hyaluronic acid (HA) gels specifically designed to deliver long-lasting, natural. |
businesswire.com |
2025-04-15 12:00:00 |
Czytaj oryginał (ang.) |
| Evolus to Participate in The Needham 24th Annual Virtual Healthcare Conference |
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced that members of its management team will participate in a fireside chat and investor meetings at the upcoming Needham Annual Virtual Healthcare Conference. The fireside chat will take place on Tuesday, April 8, 2025, at 12:45 PM ET - Track 1. The fireside chats can be accessed on the Investor Relations page of the Evolus website here. |
businesswire.com |
2025-03-25 10:00:00 |
Czytaj oryginał (ang.) |
| Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of 29,763 restricted stock units (RSUs) of the company's common stock to 14 newly hired non-executive employees of the company. The awards were approved by the compensation committee of the company's board of directors under the Evolus' 2023 Inducement Incentive Plan, with a grant and vesting commencement d. |
businesswire.com |
2025-03-21 18:05:00 |
Czytaj oryginał (ang.) |
| Evolus, Inc. (EOLS) Q4 2024 Earnings Call Transcript |
Evolus, Inc. (NASDAQ:EOLS ) Q4 2024 Earnings Conference Call March 4, 2025 4:30 PM ET Company Participants Nareg Sagherian - VP and Head of Global IR and Corporate Communications David Moatazedi - President and CEO Rui Avelar - Chief Medical Officer and Head of R&D Sandra Beaver - CFO Conference Call Participants Annabel Samimy - Stifel Gangireddy Madhumitha - Stryker Navann Ty - BNP Paribas Doug Tsao - H.C. Wainwright Serge Belanger - Needham & Company Operator Good afternoon, everyone, and thank you for standing by. |
seekingalpha.com |
2025-03-05 01:18:09 |
Czytaj oryginał (ang.) |
| Evolus, Inc. (EOLS) Q4 Earnings and Revenues Lag Estimates |
Evolus, Inc. (EOLS) came out with quarterly earnings of $0.01 per share, missing the Zacks Consensus Estimate of $0.06 per share. This compares to loss of $0.14 per share a year ago. |
zacks.com |
2025-03-04 20:25:27 |
Czytaj oryginał (ang.) |
| Evolus posts quarterly profit on strong sales of cosmetic injection |
Cosmetic drugmaker Evolus reported a fourth-quarter profit versus a year-ago loss on Tuesday, on strong demand for its wrinkle treatment Jeuveau which competes with Botox. |
reuters.com |
2025-03-04 18:17:02 |
Czytaj oryginał (ang.) |
| Evolus Reports Record Fourth Quarter and Full-Year 2024 Financial Results; Reaffirms 2025 Guidance |
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced its financial results for the fourth quarter and full-year ended December 31, 2024. “We reached a significant inflection point in 2024, achieving full-year profitability1 ahead of expectations while delivering our fifth consecutive year of revenue growth exceeding 30%,” said David Moatazedi, President and Chief Executive Officer of Ev. |
businesswire.com |
2025-03-04 18:05:00 |
Czytaj oryginał (ang.) |
| Evolus to Participate in the TD Cowen 2nd Annual Glowing Ahead: Beauty & Wellness Summit |
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced that members of its management team will participate in the TD Cowen 2nd Annual Glowing Ahead: Beauty & Wellness Summit in New York City on Thursday, February 27, 2025. As part of the event, David Moatazedi, President and CEO of Evolus, will host a fireside chat on Thursday, February 27, 2025, from 9:30 AM – 10:00 AM ET. A live we. |
businesswire.com |
2025-02-20 10:00:00 |
Czytaj oryginał (ang.) |
| Evolus to Report Fourth Quarter and Year End 2024 Results on March 4, 2025 |
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its fourth quarter and year end 2024 financial results on Tuesday, March 4, 2025, after the U.S. financial markets close. Evolus management will host a conference call and live webcast to discuss these results at 4:30 p.m. ET that same day. A question-and-answer session will follow management's r. |
businesswire.com |
2025-02-18 10:00:00 |
Czytaj oryginał (ang.) |
| Evolus (EOLS) Moves 5.5% Higher: Will This Strength Last? |
Evolus (EOLS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term. |
zacks.com |
2025-02-14 11:57:11 |
Czytaj oryginał (ang.) |
| US FDA approves Evolus' anti-wrinkle gels |
Evolus said on Thursday the U.S. Food and Drug Administration has approved its two new anti-wrinkle injectable gels, expanding the company's product portfolio beyond its cosmetic injection Jeuveau. |
reuters.com |
2025-02-13 15:45:53 |
Czytaj oryginał (ang.) |
| Evolus Announces FDA Approval of Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels |
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced that the U.S. Food and Drug Administration (FDA) has approved Evolysse™ Form and Evolysse™ Smooth injectable hyaluronic acid (HA) gels, the first two products in the Evolysse™ collection. These approvals mark Evolus' entry into the U.S. HA dermal filler market and solidifies the company's position as a multi-product innovator in aesth. |
businesswire.com |
2025-02-13 15:30:00 |
Czytaj oryginał (ang.) |
| Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of non-qualified stock options to purchase an aggregate of 26,897 shares of Evolus and an aggregate of 99,826 restricted stock units (RSUs) of the company's common stock to 34 newly hired non-executive employees of the company. The awards were approved by the compensation committee of the company's board of. |
businesswire.com |
2025-02-07 21:09:00 |
Czytaj oryginał (ang.) |
| Evolus (EOLS) Surges 28.3%: Is This an Indication of Further Gains? |
Evolus (EOLS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term. |
zacks.com |
2025-01-22 10:51:22 |
Czytaj oryginał (ang.) |
| Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Net Revenue, Achieving Record Results at the Top of the Company's Guidance |
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio, today announced its preliminary, unaudited net revenue for the fourth quarter and full-year ended December 31, 2024. The preliminary unaudited results described in this press release are based on the most current information available to management and are subject to change until the audit of the company's 2024 financial results is completed a. |
businesswire.com |
2025-01-21 10:00:00 |
Czytaj oryginał (ang.) |
| Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant in January of an aggregate of 15,332 restricted stock units (RSUs) of the company's common stock to 6 newly hired non-executive employees of the company. The awards were approved by the compensation committee of the company's board of directors under the Evolus' 2023 Inducement Incentive Plan, with a grant. |
businesswire.com |
2025-01-17 18:05:00 |
Czytaj oryginał (ang.) |
| Evolus: Still Bullish, But Business Faces Tricky Challenges In '25 |
I previously rated Evolus, Inc. stock a “Buy” due to its litigation settlement with AbbVie, strong revenue targets, and promising product performance. Despite positive updates, Evolus stock fell sharply, possibly due to market unpredictability and sector instability. Evolus' ambitious revenue targets and profitability projections face skepticism, but strong product performance and brand loyalty offer optimism. |
seekingalpha.com |
2025-01-14 16:00:40 |
Czytaj oryginał (ang.) |
| Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant in November non-qualified stock options to purchase an aggregate of 9,872 shares of Evolus and an aggregate of 16,596 restricted stock units (RSUs) of the company's common stock to 9 newly hired non-executive employees of the company (the “November Grants”). The Company also is reporting the grant in Decemb. |
businesswire.com |
2024-12-13 18:05:00 |
Czytaj oryginał (ang.) |
| Here's Why Evolus (EOLS) Could be Great Choice for a Bottom Fisher |
Evolus (EOLS) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term. |
zacks.com |
2024-11-18 12:55:36 |
Czytaj oryginał (ang.) |
| Down -29.8% in 4 Weeks, Here's Why You Should You Buy the Dip in Evolus (EOLS) |
Evolus (EOLS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock. |
zacks.com |
2024-11-14 12:35:15 |
Czytaj oryginał (ang.) |
| Evolus, Inc. (EOLS) Reports Q3 Loss, Misses Revenue Estimates |
Evolus, Inc. (EOLS) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to loss of $0.19 per share a year ago. |
zacks.com |
2024-11-06 21:26:16 |
Czytaj oryginał (ang.) |
| Evolus Reports Third Quarter 2024 Results |
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported financial results for the third quarter ended September 30, 2024, and provided a business update. “Our third quarter results underscore the momentum we've been building throughout the year,” said David Moatazedi, President and Chief Executive Officer. “We continue to deliver growth at multiples above the market, vali. |
businesswire.com |
2024-11-06 18:05:00 |
Czytaj oryginał (ang.) |
| Evolus to Participate in Stifel 2024 Healthcare Conference |
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced that members of its management team will present at the Stifel Healthcare Conference in New York City on Tuesday, November 19 at 10:55 AM ET. The presentation can be accessed on the Investor Relations page of the Evolus website here. A replay of the webcast will be available for 90 days after the date of the presentation. About Evolus. |
businesswire.com |
2024-11-01 10:00:00 |
Czytaj oryginał (ang.) |
| Evolus Announces EU Approval of Estyme® Injectable Hyaluronic Acid Gels Under New Medical Device Regulation |
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the EU Medical Device Regulation (MDR) certification was received for four unique injectable hyaluronic acid (HA) gels under the brand name Estyme® (pronounced “esteem”), branded as Evolysse™ in the U.S. market. This certification marks a key regulatory milestone for Evolus, enabling it to commercially enter the der. |
businesswire.com |
2024-10-31 16:02:00 |
Czytaj oryginał (ang.) |
| Will Evolus, Inc. (EOLS) Report Negative Earnings Next Week? What You Should Know |
Evolus (EOLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2024-10-30 13:06:44 |
Czytaj oryginał (ang.) |
| Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of non-qualified stock options to purchase an aggregate of 10,251 shares of Evolus and an aggregate of 31,049 restricted stock units (RSUs) of the company's common stock to 16 newly hired non-executive employees of the company. Additionally, the compensation committee approved the grant of individually nego. |
businesswire.com |
2024-10-12 02:53:00 |
Czytaj oryginał (ang.) |
| Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of an aggregate of 10,845 restricted stock units (RSUs) of the company's common stock to 5 newly hired non-executive employees of the company. The awards were approved by the compensation committee of the company's board of directors under the Evolus' 2023 Inducement Incentive Plan, with a grant date of Sep. |
businesswire.com |
2024-09-28 01:00:00 |
Czytaj oryginał (ang.) |
| Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant in July an aggregate of 46,363 restricted stock units (RSUs) of the company's common stock to 16 newly hired non-executive employees of the company (the “July Grants”). The Company also is reporting the grant in August of an aggregate of 35,921 RSUs and non-qualified stock options to purchase an aggregate o. |
businesswire.com |
2024-08-09 20:30:00 |
Czytaj oryginał (ang.) |
| Evolus, Inc. (EOLS) Q2 2024 Earnings Call Transcript |
Evolus, Inc. (NASDAQ:EOLS ) Q2 2024 Earnings Conference Call July 31, 2024 4:30 PM ET Company Participants Nareg Sagherian - Vice President and Head of Global Investor Relations and Corporate Communications David Moatazedi - President and CEO Sandra Beaver - CFO Rui Avelar - Chief Medical Officer and Head of R&D Conference Call Participants Jack Padovano - Stifel Navann Ty - BNP Serge Belanger - Needham & Company Operator Good afternoon, everyone and thank you for standing by. Welcome to Evolus' Second Quarter 2024 Earnings Conference Call. |
seekingalpha.com |
2024-08-01 02:22:05 |
Czytaj oryginał (ang.) |
| Evolus, Inc. (EOLS) Reports Q2 Loss, Tops Revenue Estimates |
Evolus, Inc. (EOLS) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.22 per share a year ago. |
zacks.com |
2024-07-31 23:46:33 |
Czytaj oryginał (ang.) |
| Evolus reports first-ever adjusted profit in Q2 fueled by strong sales of Botox rival |
Evolus , an anti-wrinkle injection maker, reported its first-ever quarterly profit on an adjusted basis on Wednesday, driven by strong sales of its Botox rival Jeuveau. |
reuters.com |
2024-07-31 20:09:16 |
Czytaj oryginał (ang.) |
| Evolus, A Medical Aesthetics Player, Becomes Profitable — Two Quarters Early |
Medical aesthetics company Evolus notched its first-ever profits late Wednesday — two quarters ahead of expectations. |
investors.com |
2024-07-31 20:05:36 |
Czytaj oryginał (ang.) |
| Evolus to Report Second Quarter Financial Results on July 31, 2024 |
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its second quarter 2024 financial results on Wednesday, July 31, 2024, after the U.S. financial markets close. Evolus management will host a conference call and live webcast to discuss these results at 4:30 p.m. ET that same day. A question-and-answer session will follow management's remarks. To. |
businesswire.com |
2024-07-17 12:00:00 |
Czytaj oryginał (ang.) |
| Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for First Two Evolysse™ Dermal Filler Products |
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it has submitted the final module of its premarket approval (PMA) application to the U.S. Food and Drug Administration (FDA) for the Evolysse™ Lift and Evolysse™ Smooth dermal filler products for the nasolabial fold (NLF). “We are pleased to have submitted the final module of the PMA application,” said Dr. Rui. |
businesswire.com |
2024-06-24 12:00:00 |
Czytaj oryginał (ang.) |
| Evolus Broadens International Presence with Launch of Nuceiva® (botulinum toxin type A) in Spain |
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company focused on building an aesthetic portfolio, has commercially launched Nuceiva® (botulinum toxin type A) in Spain. The product is now available for direct order and delivery to Spanish medical aesthetics healthcare professionals. Nuceiva® is approved by the European Commission for the temporary improvement in the appearance of moderate to severe vertical lines between the eyebrows seen at maximum fr. |
businesswire.com |
2024-06-12 12:00:00 |
Czytaj oryginał (ang.) |
| Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of non-qualified stock options to purchase an aggregate of 30,778 shares of Evolus and an aggregate of 29,546 restricted stock units (RSUs) of the company's common stock to 9 newly hired non-executive employees of the company. The awards were approved by the compensation committee of the company's board of. |
businesswire.com |
2024-06-07 21:00:00 |
Czytaj oryginał (ang.) |
| Evolus (EOLS) Releases Favorable Dermal Fillers Study Data |
The addition of Evolysse fillers to the company's portfolio complements Evolus' (EOLS) flagship neurotoxin Jeuveau. |
zacks.com |
2024-05-21 16:01:20 |
Czytaj oryginał (ang.) |